Hospital Medicine Unplugged

In this episode of Hospital Medicine Unplugged, we run the inpatient anticoagulation playbook—pick the right drug, dose it safely, and dodge both clots and bleeds.
We start with why we anticoagulate in hospital: VTE treatment and prophylaxis, AF stroke prevention, ACS, and valve/bridging scenarios—always walking the tightrope between thrombosis and bleeding. Then we map the four main drug classes:• DOACs as default for most nonvalvular AF and VTE—rapid onset, predictable PK, no routine monitoring, but no go in mechanical valves, APS, pregnancy, or severe CKD.• LMWH as the inpatient workhorse—VTE treatment and prophylaxis, cancer, pregnancy, lower HIT and osteoporosis risk, but renally cleared and only partially reversible.• UFH as the rescue drug—severe renal failure, high bleeding risk, need for rapid on/off, thrombolysis, or upcoming procedures.• Warfarin for the “can’t DOAC” crowd—mechanical valves, rheumatic MS, triple-positive APS, advanced CKD/liver disease—with INR targets, monitoring, and all the interaction baggage.
From there we build a clinical decision framework:• Renal and hepatic function drive DOAC vs LMWH vs UFH vs warfarin.• Bleeding risk (HAS-BLED, IMPROVE) and prior GI bleed shape how hard you push.• Drug–drug interactions (CYP3A4/P-gp, polypharmacy, antiplatelets/NSAIDs) push you toward or away from certain DOACs or warfarin.• Extremes of body weight, procedures on the horizon, and the need for a reversal plan all feed into the choice.
For VTE treatment, we compare:• Stable DVT/PE with good kidneys → DOAC first (EINSTEIN, AMPLIFY, Hokusai).• Cancer-associated VTE → DOACs vs LMWH: DOACs now common, but LMWH still preferred for GI/GU tumors or very high bleeding risk.• Severe CKD or tenuous bleeder → UFH infusion with aPTT-guided titration and protamine in your back pocket.• Mechanical valves or APS → warfarin with bridging.
For VTE prophylaxis, we keep it practical:• LMWH (enoxaparin/dalteparin) as first-line in most medical/surgical inpatients.• UFH for CrCl <30 or when you need a super short half-life.• DOACs (rivaroxaban, betrixaban) as select tools for extended prophylaxis, not routine inpatient starters.• Warfarin stays out of acute prophylaxis.
We also tackle cardiology use cases:• UFH (or bivalirudin) for ACS/PCI.• Enoxaparin as an alternative in NSTE-ACS/unstable angina when managed medically.• DOACs and warfarin move to the long-game: AF, LV thrombus, and post-ACS patients who need both antiplatelets and anticoagulation.
Finally, we walk through special populations:• Severe CKD → UFH first; dose-reduced LMWH or off-label apixaban only with eyes wide open.• Morbid obesity or very low weight → how we think about fixed-dose DOACs, weight-based LMWH, and when to consider anti-Xa levels.• Pregnancy → LMWH only, no DOACs or warfarin.• Cancer → choosing between DOACs and LMWH based on tumor site, bleeding risk, kidneys, and patient preferences.
We close with a bedside checklist: define the indication, check kidney/liver function, estimate bleeding risk, scan the med list for interactions, ask “how fast do I need on/off?”, then lock in an agent, dose, monitoring plan, and a clear reversal strategy. Right drug, right patient, right moment—while keeping both clots and bleeds off your service list.

In this episode of Hospital Medicine Unplugged, we unpack iron deficiency anemia (IDA) and anemia of chronic disease/inflammation (ACD/AI)—absolute iron depletion versus hepcidin-driven iron lock-down, and why that distinction matters on the wards.
We sprint through the core physiology: IDA runs on empty iron stores—low ferritin, low TSAT, low hepcidin, microcytosis. ACD/AI keeps iron trapped inside macrophages—normal/high ferritin, low TSAT, low transferrin, high hepcidin—producing a functional deficiency despite adequate stores.
Diagnosis starts with the do-first labs: CBC with indices, smear, ferritin, serum iron, TIBC, TSAT, CRP, ± soluble transferrin receptor (sTfR) and reticulocyte Hb. Ferritin <30 ng/mL screams IDA, but in inflammation we need a higher cutoff (<100). sTfR high = IDA; normal = ACD/AI. Hepcidin stays low in IDA, high in ACD.
Symptom patterns help but aren’t definitive: IDA brings classic iron-depletion clues (pica, restless legs, glossitis), while ACD/AI blends into the underlying chronic disease. Overlap syndromes blur the picture—ferritin “normal,” TSAT low, inflammation high—the most common and the most misdiagnosed group in the hospital.
Management stays principle-driven:• Treat the cause first—stop the bleed, fix malabsorption, control inflammation.• Replete iron: oral every-other-day for pure IDA; IV iron for inflammation, malabsorption, or rapid repletion needs.• ACD/AI leans on underlying disease control; ESA therapy only in selected CKD/cancer patients.• Overlap syndromes? Think IV iron early; oral will fail against hepcidin.
Risk matters: anemia on admission predicts longer stay, higher readmission, and higher mortality. The sickest group—older adults with multiple comorbidities—often has mixed pathology and needs aggressive evaluation and structured follow-up every 3–6 months with CBC and iron studies.
We close with future directions: hepcidin antagonists, HIF-PH inhibitors, and precision biomarkers (hepcidin, sTfR) that may finally crack the code of inflammation-mediated iron restriction. For now, stick to the fundamentals: identify absolute vs functional deficiency, interpret ferritin through the lens of inflammation, choose the right route for iron, and never overlook an “inappropriately normal” ferritin.

In this episode of Hospital Medicine Unplugged, we crack open Against Medical Advice (AMA) discharges—why patients walk, who’s at highest risk, what really happens after they leave, and how to respond in a way that’s ethical, patient-centered, and legally defensible.
We start with the basics: AMA = patients leaving before the team thinks it’s safe. It’s only ~1–2% of discharges, but clustered in younger patients, men, people with substance use and psychiatric disorders, those who are uninsured, on Medicaid, or homeless, and especially anyone with a prior AMA history. We unpack how structural factors—poverty, racism, housing instability, insurance gaps—drive “noncompliance” more than patient personality.
Then we lay out the consequences: ~2× higher 30-day readmissions, a 2×+ bump in mortality, tons of early bounce-backs within 24 hours, and hundreds of thousands of hospital days and dollars burned. We connect the dots: shortened LOS, interrupted treatment, no meds, no follow-up, and patients showing up sicker at a different hospital.
From there we get practical at the bedside:
Capacity, always first. We walk through the 4 pillars—understanding, appreciation, reasoning, choice—and how to optimize capacity by treating delirium, intoxication, withdrawal, pain, and metabolic derangements before you even think about AMA.
Risk stratification by diagnosis: MI, sepsis, DKA, respiratory failure, trauma, psychiatric emergencies—what leaving early actually means for morbidity and mortality in each bucket.
Find the modifiable drivers: undertreated pain, unmanaged withdrawal, nicotine craving, childcare, job loss fears, transportation, homelessness, mistrust, and prior bad experiences with the system.
Communication is the pivot. We lean into nonjudgmental, empathic conversations, motivational interviewing, and de-escalation. We break down the AIMED framework—Assess, Investigate, Mitigate, Explain, Document—as a stepwise way to turn “I’m leaving” into “How can we make this safer?” without coercion or power struggles.
For high-risk groups with OUD and other SUDs, we focus on what actually moves the needle:
Early, in-hospital MOUD (buprenorphine/methadone) to cut AMA and readmissions.
Aggressive pain and withdrawal management, not just PRN clonidine.
Addiction consult services to initiate MOUD, link to OTPs/bridge clinics, and coordinate post-discharge care.
We zoom out to operational fixes: better discharge communication, individualized discharge plans, streamlined prescriptions, solving basics like transportation and childcare, and targeted workflows in high-risk units (ED, medicine, psych).
Then we get into documentation and legal protection—what has to be in the note so “AMA” actually means something:
Explicit capacity assessment (by element).
Concrete risks, benefits, and alternatives discussed (including partial treatment).
What the team offered to mitigate harm (pain control, MOUD, rides, follow-up).
The patient’s reasons in their own words.
Why the team judged the plan clinically reasonable at the time.
We stress the limits of AMA forms and why the contemporaneous narrative note, free of stigmatizing language, is your real medicolegal shield.
Finally, we tackle ethics and high-risk scenarios: autonomy vs beneficence, when persuasion becomes coercion, the difference between capacity and legal competence, and how AMA is different for minors, patients on involuntary holds, or those with guardianships. We close with harm-reduction discharges—provisional prescriptions, naloxone, wound supplies, rapid follow-up—and how to welcome patients back after an AMA episode without shame or blame.
Fast, structured, and equity-focused—identify who’s likely to leave, fix what’s fixable, communicate without stigma, build harm-reduction exits, document like it matters, and never confuse “AMA” with “we’re done caring.”

In this episode of Hospital Medicine Unplugged, we dive into evidence-based, hospital-focused management of resistant hypertension—a condition affecting up to 1 in 5 hypertensive adults and carrying ≥50% higher risk of MI, stroke, ESKD, and cardiovascular death.
We start by drawing the line between true resistant hypertension (BP above goal despite 3 complementary agents including a diuretic, or controlled BP on ≥4 meds) and the look-alikes: refractory HTN (uncontrolled on ≥5 agents including an MRA) and malignant HTN (acute end-organ damage). In the hospital, we must separate chronic resistant HTN from acutely uncontrolled BP driven by pain, anxiety, missed meds, volume shifts, or acute illness.
Our first task: rule out pseudoresistance. That means fixing measurement errors, restarting home meds, identifying nonadherence, assessing pain and volume status, and removing BP-raising drugs—NSAIDs, steroids, sympathomimetics, calcineurin inhibitors, erythropoietin, excess IV fluids, and more. We emphasize the ACC/AHA message: 20% of hypertensive adults regularly take interfering medications, and up to 41% of hospitalized patients miss home antihypertensives.
Next, we confirm true resistance with out-of-office BP—home BP or, ideally, ABPM, since white-coat resistant HTN carries far lower long-term cardiovascular risk than true resistance. If the numbers hold, we move into systematic secondary evaluation: primary aldosteronism, OSA, renal parenchymal disease, renovascular disease, and medication-induced hypertension.
Treatment opens with the guideline-backed triple therapy backbone:• ACE-I/ARB + long-acting CCB + thiazide-like diuretic (chlorthalidone/indapamide preferred).• Below eGFR 40–45: switch thiazides to loop diuretics, typically q12h dosing.
Then we deploy the fourth-line star: spironolactone 25–50 mg, the most effective agent based on RCTs and network meta-analyses, cutting 24-hour SBP by ~7–9 mm Hg. But since 4–40% cannot tolerate spironolactone, we cover alternatives:• Amiloride (10–20 mg)—equally effective in trials• Eplerenone—better tolerated hormonally, less potent BP reduction• Consider finerenone in CKD with albuminuria (role in resistant HTN still emerging)
For fifth-line therapy, we reserve beta-blockers, alpha-blockers, clonidine, and direct vasodilators—but hydralazine/minoxidil must be paired with a β-blocker + loop diuretic to blunt reflex tachycardia and fluid retention.
We also break down renal denervation, which offers modest (~3–5 mm Hg) 24-hour SBP reduction but lacks long-term CVD outcome data. Aprocitentan, FDA-approved in 2025, adds another option, though edema (9–18%) limits use in volume-sensitive patients.
CKD deserves its own playbook: resistant HTN is twice as common in CKD, thiazides lose power as GFR falls, and aldosterone excess plus sympathetic activation fuel volume-driven hypertension. We outline strategies including loop diuretics, cautious low-dose MRAs with potassium binders, and the evolving role of nonsteroidal MRAs.
Throughout, we reinforce that intensive BP control matters. For resistant HTN, pooled SPRINT/ACCORD analyses show similar benefit from a systolic target <120 mm Hg—when tolerated—cutting major CV events and mortality.
We close with a hospital-ready framework:• Fix pseudoresistance first—measurement, meds, volume, pain, interfering agents• Confirm with out-of-office BP• Screen systematically for secondary causes• Build the ACE/ARB + CCB + potent diuretic foundation• Add spironolactone, or amiloride/ eplerenone when needed• Use advanced agents and devices selectively• Individualize BP targets while avoiding overcorrection of asymptomatic inpatient BP spikes
Volume control, aldosterone blockade, clean med lists, and accurate BP data—that’s how you turn apparent chaos into controlled, evidence-based management of resistant hypertension in the hospital.

In this episode of Hospital Medicine Unplugged, we tackle opioid withdrawal on the inpatient ward—a syndrome that’s not usually lethal, but absolutely destabilizing, deeply uncomfortable, and a leading driver of patient-directed discharge.
We open with why this matters now: fentanyl has changed everything. Its high potency and lipophilicity make withdrawal more severe, more unpredictable, and often prolonged, leaving standard opioid agonist approaches underpowered. Add in common polysubstance use—stimulants, benzodiazepines, xylazine—and clinicians must often manage multiple withdrawal syndromes in parallel.
Diagnosis starts with timing: 8–12 hours after short-acting opioids, 8–24 hours after fentanyl, up to 30 hours after methadone. Patients present with the classic multisystem storm—autonomic activation (sweating, tachycardia, piloerection, dilated pupils), GI distress, myalgias, and intense craving. We rely on COWS and SOWS for objective tracking; SOWS often detects symptoms earlier, COWS guides treatment thresholds.
But step one is simple: ask about withdrawal and treat it aggressively. Untreated withdrawal drives AMA discharges, worsens medical illness, and erodes trust. Starting MOUD early lowers AMA discharge risk by ~27%.
Treatment goals are clear: rapid symptom relief, stabilize with opioid agonists, prevent complications, and set up continuity of care.
Our backbone: opioid agonist therapy.
• Methadone shines here—no need to wait for withdrawal, no risk of precipitated withdrawal, and a full agonist profile that suits high-tolerance fentanyl users. Standard starts (20–30 mg/day) often fall short in the fentanyl era; rapid inpatient titration is increasingly used safely under monitoring. Watch QTc and delayed respiratory depression.
• Buprenorphine brings a stellar safety profile and easy outpatient continuation. But it demands mild–moderate withdrawal (COWS >10) to avoid precipitated withdrawal—still a real fear among fentanyl-exposed patients. Enter microdosing/low-dose induction, now routinely used to bridge patients onto buprenorphine without requiring abstinence.
• Some centers use slow-release oral morphine for patients with QTc issues or previous induction failures, and emerging inpatient data support short-acting full-agonist opioids as adjuncts for severe fentanyl withdrawal when standard regimens aren’t enough.
If patients decline opioid agonists, we move to symptom-targeted therapy:
• Alpha-2 agonists (clonidine, lofexidine) reduce autonomic symptoms; lofexidine offers less hypotension.• GI agents (loperamide, ondansetron, dicyclomine) smooth out the abdominal churn.• NSAIDs/acetaminophen ease myalgias; trazodone or cautious benzodiazepine use can support sleep and anxiety.But remember—non-opioid therapy alone is inferior and reserved for patients who decline MOUD.
The differential stays broad: alcohol or benzodiazepine withdrawal, stimulant intoxication, viral GI illness, thyroid storm, adrenal crisis, and sepsis, especially in people who inject drugs. Missing these can be disastrous, so vitals, exam, and targeted labs remain central.
We close with the systems moves that make withdrawal care consistent and safe: normalize withdrawal screening, default to MOUD first, incorporate COWS/SOWS into nursing workflows, build fentanyl-aware induction pathways, manage concurrent withdrawals, and hard-wire outpatient linkage—OTP confirmation lines, buprenorphine follow-up, and harm-reduction resources.
Fast, compassionate, and evidence-driven—treat withdrawal early, stabilize with MOUD, support symptoms, and never miss a life-threatening mimic.

In this episode of Hospital Medicine Unplugged, we plug into evidence-based blood transfusion—who really needs blood, how much, and when a “top-up” quietly harms more than it helps.
We start with the big pivot: why modern practice has moved to a restrictive transfusion strategy (Hb <7 g/dL for most hemodynamically stable adults) and what the RCTs and Cochrane data actually show. We walk through nuanced thresholds for cardiac and orthopedic surgery, preexisting cardiovascular disease, ICU patients, kids, and hematologic/oncologic populations, and flag key exceptions like GI bleeding and brain injury, where the rules bend.
Then we zoom out to the menu of components: RBCs for oxygen delivery, platelets for thrombocytopenia, plasma for true coagulopathy, cryo/fibrinogen for hypofibrinogenemia, and whole blood in massive hemorrhage. We hammer home indications beyond “just the number”—symptoms, hemodynamics, rate of Hb drop, volume status—and when NOT to transfuse: mildly abnormal INRs, “just-in-case” platelets, and procedure prophylaxis that doesn’t move bleeding risk.
Massive hemorrhage gets its own sprint: what actually defines a massive transfusion, when to trigger an MTP, why balanced 1:1:1 resuscitation (RBC:plasma:platelets) improves hemorrhage control, and how to layer in TXA, calcium, fibrinogen replacement, and viscoelastic testing (TEG/ROTEM) without drowning the patient in crystalloid.
We unpack the dark side of blood: TACO, TRALI, acute and delayed hemolytic reactions, TA-GVHD, alloimmunization, and iron overload—and how restrictive thresholds, leukoreduction, irradiation, careful dosing, and slower infusion rates slash those risks. You’ll get a practical mental checklist for “this patient is getting worse during transfusion—now what?”
Zooming up to the system level, we build a patient blood management (PBM) toolkit: Choosing Wisely-aligned thresholds, single-unit RBC default with “transfuse 1, then reassess,” EMR best-practice alerts, audit-and-feedback reports, and multidisciplinary transfusion committees that actually change culture and save thousands of units (and dollars).
We close on ethics and patient-centered care: informed consent that’s real, not scripted, transfusion decisions in frail or terminally ill patients, and caring for Jehovah’s Witness and other transfusion-refusing patients using IV iron, ESAs, cell salvage, hemostatic agents, and meticulous blood conservation—respecting autonomy while still practicing high-value medicine.
Restrictive, thoughtful, system-aware, and patient-centered—this episode is your playbook to give blood when it heals, withhold it when it harms, and always know why you’re hanging that unit.

In this episode of Hospital Medicine Unplugged, we take a rapid, evidence-packed tour through unintentional weight loss (UWL) in hospitalized patients—screen fast, diagnose with structure, separate fluid from true tissue loss, and never miss the reversible causes.
We open with the do-firsts: screen within 24–48 hours using MUST, NRS-2002, SNAQ, or MST; older adults get the MNA-SF. Positive screen? Move straight into GLIM—you need ≥1 phenotypic + ≥1 etiologic criterion before calling malnutrition.
Phenotypics: weight loss >5% in 6 months or >10% beyond, low BMI (<20 if <70 years; <22 if ≥70), or reduced muscle mass (BIA, DXA, CT, ultrasound).Etiologics: reduced intake/assimilation or inflammation/disease burden—the cytokine-driven catabolic engine that overrides normal starvation physiology.
We highlight the epidemiology: UWL hits 20–50% of hospitalized older adults and drives higher mortality, LOS, functional decline, and readmissions—often independent of disease severity. Causes cluster into malignancy, GI disease, psychiatric disease, endocrine disorders, chronic infections, and a surprisingly large fraction (6–28%) with no clear etiology even after thorough workup.
Then the diagnostic sprint: CBC, BMP/CMP, LFTs, ultrasensitive TSH, CRP/ESR, LDH, UA, and age-appropriate cancer screenings. Chest radiography + fecal occult blood testing are universal; abdominal ultrasound or CT follows red flags. GI symptoms trigger stool culture, O&P, C. diff, malabsorption labs, or endoscopy. Never trust albumin or prealbumin—they track inflammation, not nutrition.
We hit the pitfalls hard: fluid shifts mimic weight loss, medications blunt taste and appetite, oral/dental disease gets missed, dysphagia hides in plain sight, and depression in older adults presents without sadness. EPI masquerades as IBS or celiac. Adrenal insufficiency is chronically underdiagnosed. Thyroid–diabetes interactions derail metabolic signals. Failure to screen early, recheck every 7–10 days, or document true intake leads to cascading errors.
Management? Treat the cause and build the nutritional core. Energy 20–30 kcal/kg and protein 0.8–1.5 g/kg, tailored to inflammation severity. For confirmed malnutrition, dietitian-led counseling + fortified oral supplements improve outcomes across major RCTs. Medication reconciliation is mandatory; polypharmacy wrecks appetite. Address oral pain, dentition, dysphagia, and social barriers.
We zoom in on hospital-acquired malnutrition—driven by fasting orders, mealtime interruptions, poor food service quality, inadequate feeding assistance, multimorbidity, and long LOS. Solutions use organizational muscle: protected mealtimes, dietitian-MD collaboration, patient-centered menus, protocolized swallow evaluation, early mobility, and automated rescreening.
For complex cases, we pull in the consultants:• GI for EPI, celiac, IBD, structural lesions• Endocrinology for thyroid disease, diabetes interactions, adrenal insufficiency• Psychiatry for depression, appetite changes, cognitive decline• ID for TB, HIV, chronic infections• Nutrition for intake monitoring, body composition, and intervention planning
We close with the system moves: a UWL bundle that (1) screen-within-48h defaults; (2) GLIM-confirmation pathways; (3) early imaging + stool studies when indicated; (4) intake-tracking dashboards; (5) medication-effect flags; (6) fluid-vs-tissue differentiation via calf circumference + composition tools; (7) 7–10-day reassessment; (8) multidisciplinary escalation; and (9) cause-specific tracks (malabsorption, malignancy, endocrine, psychiatric).
Fast, structured, and inflammation-aware—screen early, diagnose precisely, distinguish fluid from tissue, treat the cause, and don’t let hospital factors sabotage recovery.

In this episode of Hospital Medicine Unplugged, we tackle in-hospital falls—how often they happen, why they’re so devastating, and how to build a multifactorial, restraint-sparing prevention bundle that actually works at the bedside.
We start with the scope: typical acute-care fall rates run 1.5–4.2 falls per 1,000 patient-days, with geriatric and medical units hit hardest. Up to half of fallers are injured; in older adults, major injuries are ~8× more common, with hip fractures, subdurals, and ICH driving longer LOS, readmissions, cost, litigation, and loss of trust. Add in Joint Commission sentinel event rules and CMS non-payment for fall injuries—and you’ve got a must-fix safety problem.
Then we clean up the language: hospital falls as any unexpected descent to floor/lower level; we sort anticipated physiological (gait, weakness, meds), unanticipated physiological (delirium, new illness, syncope), and accidental (environmental). We walk through injury severity from none → minor → moderate → Major A/B/C → death, and zoom in on high-risk contexts: toileting, bed-exit, transfers, ambulation, peri-procedural.
Next, we hit what’s modifiable in hospital:• Psychotropics and other FRIDs (benzos, antidepressants, antipsychotics, sedatives, opioids, insulin, antihypertensives, high ACB burden)• Orthostatic hypotension, gait/balance deficits, muscle weakness, vision loss• Delirium, sleep disruption, pain, and continence issues• Environmental and care-related factors: clutter, lighting, equipment, staffing, and unsupervised toileting
For screening and risk strat, we ditch scored “fall risk” stickers and lead with brief admission screening (think CDC STEADI 3 questions) plus automatic high-risk flags (recent falls, injury, frailty, gait impairment). Anyone who screens positive gets multifactorial assessment: meds, orthostatics, gait/balance (TUG), cognition/delirium, vision, feet/footwear, continence, ADLs, and environment—using tools like Morse or Johns Hopkins to structure, not replace, clinical judgment.
When a fall happens, we move fast: ABCs, head-to-toe for occult injury, neuro check, hip and spine, orthostatics, targeted labs and imaging. We ask the framing question: “If this were a healthy 20-year-old, would they have fallen?” If not, we hunt for underlying pathology—arrhythmia, infection, stroke, medication toxicity—and loop in PT/OT early.
The core of the episode is the multifactorial bundle:• Medication review & deprescribing FRIDs; reschedule diuretics/antihypertensives away from night• Supervised exercise & mobility: strength, balance, functional training; no “bed rest by default”• Environmental optimization: lighting, clutter, bed height, grab bars, walking aids within reach• Delirium prevention/management: orientation, sleep hygiene, sensory aids, early mobilization• Toileting protocols: scheduled voids, timely assistance, prioritize bathroom & bed-exit safety• Nutrition & vitamin D where indicated• Patient, family, and staff education as a high-yield, low-tech intervention
We zoom in on special populations—very old, cognitively impaired, Parkinson’s, post-op, rehab and ICU patients—where falls are frequent and injuries severe. Here we stress person-centered care, care-partner involvement, sustained exercise, and balancing the tension between mobility and risk aversion.
Then we tackle the controversies: physical restraints, bed/chair alarms, sitters, and high-tech sensors. We review why the evidence shows little benefit and real harm—more delirium, more device removal, more meds, longer stays—and how guidelines are shifting towards least-restraint, engagement-based models instead of “alarm everything.”
We close with the post-fall and QI playbook: standardized post-fall assessment, a quick bedside huddle, unit-level root cause analysis, and using tools like Fall TIPS-style bedside plans to translate risk factors into visible, actionable precautions. We outline how to build a falls bundle into your order sets, nursing flowsheets, handovers, and dashboards so prevention is baked into the system, not bolted on.
Fast, pragmatic, and systems-focused—recognize the modifiable risks, screen smart, build a tailored multifactorial bundle, stop over-relying on restraints and alarms, and treat every fall as a trigger for better design, not blame.